The Role of the Interleukin-1–Receptor Antagonist in Blocking Inflammation Mediated by Interleukin-1 Author : Charles A. Dinarello , M.D. Author Info & Affiliations Published September 7, 2000 ...

A multicenter, double-blind, dose ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression ...

Researchers described the detection of a human interleukin-1β antagonist with low molecular weight that disrupts interactions with the interleukin-1 receptor type I receptor.

Tocilizumab, a novel IL-6R inhibitor, may be beneficial for the treatment of RA in patients who do not respond to methotrexate or disease-modifying antirheumatic drugs.

The FDA approved dupilumab (Dupixent) as the first targeted drug for bullous pemphigoid, a rare blistering skin disease that ...

IL-1ra is a competitive antagonist of IL-1R1 that selectively binds, but fails to trigger receptor association with the accessory protein resulting in blockade of all known actions of IL-1. A ...

Objectives Achilles tendinopathy (AT) is a multifactorial condition for which genetic risk factors have been identified. A pathway-based approach was used to investigate genes within the inflammatory ...